In partnership with PTC Therapeutics, MDA will host a July 6 webinar at 2 p.m. Eastern time that will provide DMD families with an important update about Emflaza. PTC Therapeutics will discuss access to Emflaza and the EMFLAZACares program. At the end, there will be time for Q&A where participants will be asked to provide questions to the moderator via the webinar chat function.
The webinar is open to the first 500 callers (including those calling in with their computer). A recording will be available after July 6 on mda.org.
Instructions to join the webinar
- Click here to join the webinar.
- Click “Join Now” and allow the meeting time to load.
- After you log in, use the phone number, access code and attendee ID that pops up on your screen. You must have an attendee ID to attend.
Need to call in using your computer? Select the “call using computer” option and your speakers and microphone will be activated. If you don’t have a microphone, you can listen in and view the presentation and provide questions to the moderator via the chat function.
On Feb. 9 the FDA approved deflazacort (brand name Emflaza) for the treatment of Duchenne muscular dystrophy (DMD). Emflaza is the first drug in the United States approved for use by people who are 5 years or older with DMD, regardless of genetic mutation.
Emflaza is a corticosteroid that demonstrates anti-inflammatory and immunosuppressant effects. In clinical studies, those treated with Emflaza:
- Showed improved muscle strength
- Showed slower decline in functional ability
In April, South Plainfield, N.J.-based PTC Therapeutics acquired all rights to Emflaza.